André da Costa
Senior translational and precision medicine advisory across the R&D value chain
Senior scientific and strategic leader with over 15 years of experience supporting data-driven clinical development, portfolio strategy, and biomarker-enabled decision-making from early development through launch.
What I Do
I provide selective advisory support to biotech and pharmaceutical teams, including:– Translational and precision medicine strategy for early-, mid-, and late-stage development programs
– Biomarker strategy design and implementation, from discovery to clinical application
– Clinical and portfolio decision support, integrating translational, clinical, regulatory, and value considerations
– Scientific and translational asset de-risking and due diligence
– External advisory support to R&D leadership and product teams
Experience & Perspective
I bring extensive experience operating at a portfolio and franchise level within global pharmaceutical R&D, with accountability for end-to-end development strategy across multiple therapeutic areas.– Leadership roles across global pharmaceutical R&D organizations, supporting portfolio and franchise-level strategy
– End-to-end involvement in development programs from early clinical phases through approval and launch
– Establishment and execution of biomarker and precision medicine strategies
– Contribution to companion and complementary diagnostic approaches
– Participation in senior governance and R&D decision-making forums
Focus Areas
My background spans translational science, precision medicine, and clinical development, with a strong focus on biomarker-driven decision-making and integration across preclinical, clinical, regulatory, and commercial considerations.Therapeutic Areas
– Cardiovascular diseases
– Autoimmune and immune-mediated diseases
– Dermatologic diseases
– Renal diseases
– NeurosciencesScientific & Strategic Focus
– Translational science and experimental medicine
– Precision medicine and patient stratification
– Biomarker discovery, validation, and clinical implementation
– Clinical development strategy (Phase I–III)
– Asset and portfolio de-risking
– Cross-functional R&D decision support
How I Work
– Selective, clearly scoped advisory engagements
– Senior-level, outcome-focused input
– Hourly or project-based support
– Discrete, confidential, and independent perspectiveI typically work with a limited number of engagements at a time to ensure focus and impact.
Contact
For enquiries or exploratory discussions